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Abstract
Introduction: Extragenital malignant mixed Müllerian tumor is an extremely rare presentation of malignant mixed
Müllerian tumor, especially when combined with a synchronous ovarian cancer.
Case presentation: We report the clinical course and pathologic findings of a case of mesorectal malignant mixed
Müllerian tumor with synchronous ovarian cancer, in a 50-year-old, gravida 0, para 0, Han Chinese woman with
regular menstruation. This is the sixteenth case in the English literature of extragenital malignant mixed Müllerian
tumor combined with synchronous or metachronous malignancy reported.
Conclusion: Although extragenital malignant mixed Müllerian tumor is very rare and has a poor prognososis, a
longer survival time might be achieved with treatment by cytoreductive surgery, radiotherapy and chemotherapy.
Introduction
Malignant mixed Müllerian tumor (MMMT) is an
uncommon tumor in females and the occurrence of this
disease outside the genital tract is extremely rare. In a
review of the English literature since 1955, only 48 cases
of extragenital MMMT have been reported other than
the presented case. Sixteen out of these 49 (32.7%)
extragenital MMMTs [1], including this case, were asso-
ciated with synchronous or metachronous colonic can-
cer or gynecologic malignancy and serous carcinoma of
the peritoneum (Table 1). The MMMT often presents
in elderly menopausal women and is a highly aggressive
tumor. We report the clinical course and pathologic
findings of an extragenital MMMT arising from the
mesorectum in a perimenopausal woman and a review
of the English literature.
Case presentation
The patient case was a 50-year-old, gravid 0, para 0
(G0P0), unmarried Han Chinese woman with regular
menstruation. Six months ago, she visited another medi-
cal center in Southern Taiwan for abdominal bloating,
where bilateral ovarian tumors were diagnosed. At
laparotomy, a left ovarian cystic tumor (35 × 20 × 10
cm) and a right ovarian tumor (12 × 8.5 × 6 cm) with
normal uterus and cervix were noted. An additional
tumor of about 12 × 9 × 8 cm in size was also found in
the mesorectum of the rectosigmoid colon. Resection of
the mesorectum and bilateral oophorectomy was per-
formed at the first operation at another medical center.
The histopathology report revealed bilateral ovarian can-
cer (endometrioid adenocarcinoma) and malignant
mixed Müllerian tumor from the mesorectum with
biphasic differentiation (adenocarcinomatous and spin-
dle cell sarcomatous elements). No heterologous ele-
ment was identified. No further treatment was
performed after the first time of operation. However,
she felt progressive abdominal bloating and dysuria
recently. She, therefore, visited the department of sur-
gery of our hospital. On physical examination a lower
abdominal mass was palpated. An abdominal computed
tomography scan revealed a large low density mass in
the pelvic cavity (Figure 1). The maximum size of this
lesion was about 15 cm in its long-axis diameter. This
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Laboratory tests showed that the serum lactate dehydro-
genase level was 271 IU/L. The serum CA 125 level was
elevated up to 154.3 U/mL, while the serum CA19-9
level was within the normal range.
On suspicion of the recurrence of a tumor, another
laparotomy was performed. The pelvic cavity was fully
occupied by a huge cystic mass with adjacent organ
involvement. A tumor measuring 12 × 10 × 8 cm arising
from the mesorectum was identified - the terminal
ileum was also involved. The tumor infiltrated into the
pelvic floor and the retroperitoneum and a palliative
resection of the rectosigmoid colon with an end-to-end
anastomosis was performed. Unfortunately, 10 days
later, the patient had an anastomotic leakage caused by
the penetration of the drain tube which was noted when
a colonoscopy was performed. Consequently, an ileost-
omy was constructed for fecal diversion as the healing
of the leakage site had failed. The pathologic findings
showed neoplastic cells with areas of local glandular and
squamoid differentiation. In addition, bizarre giant
tumor cells in the carcinoma component were also
noted (Figure 2A and 2B). Patternless oval to spindled
neoplastic cells were noted in the sarcoma component
Table 1 Previous reports of malignant mixed Müllerian tumor (MMMT) with synchronous or metachronous neoplasm
Case Year Author Age Primary site Tissue type Associated tumor Treatment Prognosis
1
[15]
1983 Hermann and
Tessler
72 Abdominal
retroperitoneum
Heterologous Ovarian serous papillary
carcinoma, metachronous
Operation, CT (Adriamycin
(doxorubicin), cytoxan, DTIC,
vincristine)
Death at six
months
2
[16]
1988 Chen and
Wolk
58 Pelvic
peritoneum
Homologous Ovarian serous papillary
carcinoma, metachronous
Operation, RT Death at 11
months
3
[17]
1989 El-Jabbour et
al.
76 Ascending
colon
peritoneum
Heterologous Colonic adenocarcinoma,
synchronous
Operation Death at 14 days
4
[18]
1991 Garde and
Jones et al.
65 Diaphragmatic
peritoneum
Heterologous Ovarian endometrioid
adenocarcinoma,
metachronous
Operation, CT (Adriamycin
(doxorubicin), cisplatin,
ifosfamide)
Death at six
months
5
[19]
1991 Solis et al. 54 Pelvic
peritoneum
Heterologous Serous carcinoma of
peritoneum, synchronous
Operation, CT (Adriamycin
(doxorubicin), cisplatin,
cytoxan)
Unknown
6 [9] 1994 Garamvoelgyi
et al.
59 Pelvic
peritoneum
Heterologous Endometrial
adenocarcinoma,
metachronous
Operation, CT ( ifosfamide) Death at 24
months
7 [9] 1994 Garamvoelgyi
et al.
64 Pelvic
peritoneum
Homologous Fallopian tube cacinoma
in situ, synchronous
Operation Death at eight
months
8 [9] 1994 Garamvoelgyi
et al.
84 Retrouterine
peritoneum
Heterologous Colonic adenocarcinoma,
synchronous
Operation Death at two
months from heart
disease
9
[20]
1995 Mira et al. 62 Pelvic
peritoneum
Heterologous Ovarian endometrioid
adenocarcinoma,
metachronous
Operation Survival for 28
months
10
[21]
1997 Rose et al. 71 Peritoneum Homologous Uterine cervical
adenocarcinoma,
synchronous
Operation, CT (cisplatin,
ifosfamide)
Death at six
months
11
[22]
2001 Shen et al. 33 Pelvic
peritoneum
Heterologous Endometrial
adenocarcinoma,
metachronous
Operation Death at 12
months
12
[22]
2001 Shen et al. 40 Pelvic Heterologous Fallopian tube carcinoma,
metachronous
Operation Unknown
13
[23]
2005 Mikami et al. 53 Mesentery Heterologous Fallopian tube carcinoma,
metachronous
Operation, CT Survival for six
months
14
[24]
2005 Shaco-Levy 85 Omentum Heterologous Colonic adenocarcinoma,
metachronous
Operation Survival for three
months
15
[1]
2006 Ma et al. 62 Mesentery Homologous Ovarian
adenocarcinofibroma,
synchronous
Operation, CT (ifosfamide,
carboplatin, etoposide)
Death at 30
months
16 2008 Current case 50 Mesentery Homologous Ovarian adenocarcinoma,
synchronous
Operation Death at 10
months
CT, computed tomography; DTIC, Dacarbazine; RT, radiotherapy
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CK7 and CD10 staining were positive but that the CK20
staining was negative. After one and a half months in
our department, she recovered uneventfully and was
transferred to the division of medical oncology for che-
motherapy. Chemotherapy, with regimen of bleomycin,
etoposide and cisplatin, was arranged but pancytopenia
with nosocomial infection was noted after the che-
motherapy. Due to the poor response to systemic
chemotherapy, hospice care was suggested and she was
referred to the previous medical center.
Discussion
MMMT arising from the female genital tract is a rare
disease, comprising less than 1% of all gynecological
malignancies, and MMMT of extragenital origin is even
rarer. MMMT arises from the Müllerian system which
develops to form the fallopian tubes, uterus and the
upper portion of the vagina and often occurs in meno-
pausal women. Since histological evaluation shows both
carcinoma (epithelial) and sarcoma (mesenchymal) com-
ponents, this disorder is also named carcinosarcoma.
MMMT is classified into homologous or heterologous
according to the sarcomatous component. Extragenital
MMMT can occur at any site of peritoneum and is one
type of primary peritoneal carcinomas (PPC) which was
first described by Swerdlow in 1959 [2]. It has the char-
acteristics of involvement in the peritoneum by carci-
noma without an obvious primary site [3].
The majority of PPCs present in pathology as serous
papillary carcinomas, as well as peritoneal mixed epithe-
lial carcinomas, while the extragenital MMMTs are rarely
reported. PPC is a rare cancer closely related to epithelial
ovarian cancer and develops in cells from the lining of
the pelvis and abdomen (peritoneum). These cells are
similar to the cells on the surface of the ovaries. Like
ovarian cancer, PPC tends to spread along the surface of
the pelvis and abdomen. Symptoms of patients with PPC
are similar to those with ovarian cancer, including
abdominal pain or bloating, nausea, vomiting, indigestion
and change in bowel habits. Women with PPC are
usually treated similarly to those with widespread ovarian
cancer. The therapeutic modalities include cytoreductive
surgery as much as possible, followed by the same che-
motherapy regimen administrated for ovarian cancer.
Look et al. asserted that optimal cytoreduction could sig-
nificantly improve the prognosis of patients [4]. However,
PPC is of multifocal origin, which is in contrast to ovar-
ian cancer, and usually infiltrates the peritoneal lining
surface. Consequently, cytoreductive surgery is not
always optimal and this therapeutic modality needs to be
evaluated in order to determine whether it is an appro-
priate treatment for PPC.
Most PPCs are serous papillary adenocarcinomas with
a relatively good prognosis but the primary peritoneal
M M M T ,ar a r et y p eo fP P C ,u s u a l l yh a sa nu n f a v o r a b l e
outcome according to the previous literature [5].
MMMT of extragenital origin was first reported by
Ober and Black in 1955 [6] and, until now, only 48
cases have been reported in the English literature. It has
been reported to have arisen from the peritoneum,
mesentery, omentum, spleen, diaphragm and retroperi-
toneum. Among all the reported cases, the majority
Figure 2 (A) These cells with local glandular and squamoid
differentiation were noted in the carcinomatous component
(100×). (B) The bizarre tumor giant cell was noted in the
carcinomatous component (arrow; 400x). (C) The patternless oval to
spindled neoplastic cells was noted in the sarcomatous component
(200x).
Figure 1 A large low-density mass lesion was noted in the
pelvic cavity and a significant mass effect at rectosigmoid and
bladder was also noted (arrow).
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years (range 33-87 years). Sixteen of the 49 patients
(32.7%) presented with synchronous or metachronous
malignancies including colonic (three cases), ovarian (six
cases including the present case), fallopian tubal (three
cases), endometrial (two), cervical (one) and one syn-
chronous serous carcinoma of the peritoneum. Due to a
high incidence of synchronous or metachronous colonic
cancer or gynecologic malignancy originating from the
Müllerian duct, clinicians should carefully check the
genital tract in detail during the resection of primary
MMMT.
Little information about the management of extrageni-
tal MMMT is available. All suggestions for the treat-
ment extragenital MMMT are based on individual cases.
Treatments including cytoreductive surgery and che-
motherapy have been reported. Surgical management is
usually mandatory due to the clinical presentation
caused by the mass effect. However, a radical surgical
treatment is often obtained with difficulty. It seems that
chemotherapy is more important than surgical treat-
ment and the treatment choice of MMMT is similar to
that of genital MMMT.
There are several reports regarding platinum-based
chemotherapy activity against MMMT of the ovary.
Simon et al. reported a patient with MMMT of the
ovary who had a suboptimal response to single-agent
cisplatin chemotherapy but who demonstrated a com-
plete response with ifosfamide, mesna, Adriamycin (dox-
orubicin) and dacarbazine [7]. Paclitaxel/carboplatin
(PC) or platinum/ifosfamide (PI) has been used for the
chemotherapy of ovarian MMMT [8]. The median sur-
vival time of patients receiving PC was 19 months. One
patient receiving PC as first-line treatment demonstrated
ac o m p l e t er e s p o n s ea n dw a sf r e eo fd i s e a s ea f t e r3 3
months. The median survival time of patients managed
with PI was 23 months. Three patients with suboptimal
disease demonstrated complete response after receiving
PI. This study showed the potential activity of PC in
MMMT of the ovaries should be further explored.
The role of radiotherapy remains controversial. When a
patient presents with a grossly residual tumor, radiother-
apy may be considered. Garamvoelgyi et al. reported a
patient who received postoperative radiotherapy and sur-
vived for eight months [9]. Conversely, other authors con-
sider that extragenital MMMT is one kind of PPC and is
similar to ovarian epithelial tumor. Muller et al. reported
six cases of metastasized MMMTs receiving cytoreductive
surgery plus intraperitoneal hyperthermic perfusion and
adjuvant treatment of CDDP (cis-diamminedichloroplati-
num), mitomycin and ifosfamide applied via intraaortic
catheter [10]. Four patients were found with no evidence
of disease after two, four, 14, and 19 months, respectively.
Thus, complete cytoreduction plus hyperthermic
peritoneal perfusion plus adjuvant chemotherapy seems to
be an effective treatment for recurrent or metastatic
MMMT.
A similar case of MMMT of mesenteric origin was
reported by Ma et al.[1]. The patient died of extensive
metastasis 30 months after the diagnosis of MMMT.
She received six courses of chemotherapy, including
ifosfamide, VP-16 and carboplatin, as well as eight
courses of Phyxol (paclitaxel) and cisplatin.
Recently, it has been demonstrated that the presence of
BRCA mutations may predispose to primary peritoneal
cancers and this neoplasm could be a part of the heredi-
tary breast and ovary cancer syndrome [11]. Immunohis-
tochemical studies, it is suggested that expression of CD10
should be examined - it may be one of the characteristics
of MMMT [12,13]. However, the significance of CD10
expression needs to be elucidated by further studies. Our
patient’s tumor also had an expression of CD10. Regarding
the histological component in MMMT, Ozguroglu et al.
investigated the role of carcinomatous and sarcomatous
components on the response to chemotherapy and disease
outcome. It also observed that patients with a predominat-
ing carcinomatous component had a higher therapeutic
response rate (87.5%) than those with a predominating
sarcomatous component (66.6%) [14].
Conclusion
Extragenital MMMT is extremely rare and has a poor
prognosis due to its aggressive biological behavior. Syn-
chronous or metachronous gynecologic tumors often exist
and a detailed examination of the genital tract must be
made before and during the operation. Moreover,
improved survival times would probably be obtained if
accurate diagnoses and aggressive treatment, including
cytoreductive surgery and chemotherapy, are applied early
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Abbreviations
MMMT: malignant mixed Müllerian tumor; PC: paclitaxe/carboplatin; PI:
platinum/ifosfamide; PPC: primary peritoneal carcinomas.
Acknowledgements
This work was supported by a grant from the Kaohsiung Medical University
Hospital (KMUH98-8I04) and by an Excellence for Cancer Research Center
Grant (DOH100-TD-111-002) through the funding by Department of Health,
Executive Yuan.
Author details
1Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan.
2Department of Pathology, Kaohsiung
Medical University Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan.
3Departments of Obstetrics and Gynecology, College of Medicine,
Huang et al. Journal of Medical Case Reports 2011, 5:15
http://www.jmedicalcasereports.com/content/5/1/15
Page 4 of 5Kaohsiung Medical University, Kaohsiung, Taiwan.
4Graduate Institute of
Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung,
Taiwan.
5Departments of Obstetrics and Gynecology, Kaohsiung Medical
University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
6Department of Surgery, Faculty of Medicine, College of Medicine,
Kaohsiung Medical University, Kaohsiung, Taiwan.
7Graduate Institute of
Medical Genetics, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan.
8Cancer Center, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan.
Authors’ contributions
CCH drafted the article. CJM analyzed and interpreted the patient data. WTH
photographed and interpreted the pathologic findings. TFC took part in the
critical revision. and JYW took part in the surgical approach and final
approval of the manuscript. All authors have made substantive intellectual
contributions to this study and to the manuscript and have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 October 2009 Accepted: 18 January 2011
Published: 18 January 2011
References
1. Ma CJ, Yang SF, Huang CC, Chai CY, Cheng KI, Tsai EM, Wang JY:
Malignant mixed Müllerian tumor of primary mesenteric origin
associated with a synchronous ovarian cancer. Eur J Gynaecol Oncol
2008, 29:289-293.
2. Swerdlow M: Mesothelioma of the pelvic peritoneum resembling
papillary cystadenocarcinoma of the ovary; case report. Am J Obstet
Gynecol 1959, 77:197-200.
3. Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, Bloss LP,
DiSaia PJ: Extraovarian peritoneal serous papillary carcinoma: a case-
control retrospective comparison to papillary adenocarcinoma of the
ovary. Gynecol Oncol 1993, 50:347-351.
4. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive
surgery for advanced and recurrent epithelial ovarian cancers and
papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004,
12:35-41.
5. Zhang C, Li XP, Cui H, Shen DH, Wei LH: Advanced primary peritoneal
carcinoma: clinicopathological and prognostic factor analyses. J Zhejiang
Univ Sci B 2008, 9:435-440.
6. Ober WB, Black MB: Neoplasms of the subcoelomic mesenchyme; report
of two cases. AMA Arch Pathol 1955, 59:698-705.
7. Simon S, Wang SE, Shackney S: Complete response of carcinosarcoma of
the ovary to therapy with doxorubicin, ifosfamide and dacarbazine.
Gynecol Oncol 1991, 41:161-166.
8. Sit AS, Price FV, Kelley JL, Comerd JT, Kunschner AJ, Kanbour-Shakir A,
Edwards RP: Chemotherapy for malignant mixed Müllerian tumors of the
ovary. Gynecol Oncol 2000, 79:196-200.
9. Garamvoelgyi E, Guillou L, Gebhard S, Salmeron M, Seematter RJ, Hadji MH:
Primary malignant mixed Müllerian tumor (metaplastic carcinoma) of
the female peritoneum. A clinical, pathologic, and immunohistochemical
study of three cases and a review of the literature. Cancer 1994,
74:854-863.
10. Müller H, Nakchbandi V: Cytoreductive surgery plus intraperitoneal
hyperthermic perfusion is an effective treatment for metastasized
malignant mixed mesodermal tumours (MMMT) - report of six cases. Eur
J Surg Oncol 2004, 30:573-577.
11. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F,
Rohaman JA, Robson ME, Offit K, Barakat RR, et al: Fallopian tube and
primary peritoneal carcinomas associated with BRCA mutations. Clin
Oncol 2003, 21:4222-4227.
12. Mikami Y, Hata S, Kiyokawa T, Manabe T: Expression of CD10 in malignant
Müllerian mixed tumors and adenosarcomas: an immunohistochemical
study. Mod Pathol 2002, 15:923-930.
13. Gallardo A, Prat J: Müllerian adenosarcoma: a clinicopathologic and
immunohistochemical study of 55 cases challenging the existence of
adenofibroma. Am J Surg 2008, 20:278-288.
14. Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, Sahinler I:
Determining predominating histological component in malignant mixed
Müllerian tumors: is it worth it? Int J Gynecol Cancer 2008, 18:809-812.
15. Herman CW, Tessler AN: Extragenital mixed heterologous tumor of
Müllerian type arising in retroperitoneum. Urology 1983, 22:49-50.
16. Chen KT, Wolk RW: Extragenital malignant mixed Müllerian tumor.
Gynecol Oncol 1988, 30:422-426.
17. El-Jabbour JN, Helm CW, McLaren KM, Smart GE, Aitken J: Synchronous
colonic adenocarcinoma and extragenital malignant mixed mesodermal
tumour. Scott Med J 1989, 34:567-568.
18. Garde JR, Jones MA, McAfee R, Tarraza HM: Extragenital malignant mixed
Müllerian tumor: review of the literature. Gynecol Oncol 1991, 43:186-190.
19. Solis OG, Bui HX, Malfetano JH, Ross JS: Extragenital primary mixed
malignant mesodermal tumor. Gynecol Oncol 1991, 43:182-185.
20. Mira JL, Fenoglio-Preiser CM, Husseinzadeh N: Malignant mixed Müllerian
tumor of the extraovarian secondary Müllerian system. Report of two
cases and review of the English literature. Arch Pathol Lab Med 1995,
119:1044-1049.
21. Rose PG, Rodriguez M, Abdul-Karim FW: Malignant mixed Müllerian tumor
of the female peritoneum: treatment and outcome of three cases.
Gynecol Oncol 1997, 65:523-525.
22. Shen DH, Khoo US, Xue WC, Ngan HY, Wang JL, Liu VW, Chan YK,
Cheung AN: Primary peritoneal malignant mixed Müllerian tumors. A
clinicopathologic, immunohistochemical, and genetic study. Cancer 2001,
91:1052-1060.
23. Mikami M, Kuwabara Y, Tanaka K, Komiyama S, Ishikawa M, Hirose T:
Malignant mixed Müllerian tumor of primary mesenteric origin. Int J
Gynecol Cancer 2005, 15:1249-1253.
24. Shaco-Levy R, Sion-Vardy N, Piura B: Primary peritoneal malignant mixed
Müllerian tumor associated with colonic adenocarcinoma. Eur J Gynaecol
Oncol 2005, 26:509-510.
doi:10.1186/1752-1947-5-15
Cite this article as: Huang et al.: Primary malignant mixed Müllerian
tumor arising from the mesorectum with a synchronous ovarian cancer:
a case report and review of the literature. Journal of Medical Case Reports
2011 5:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huang et al. Journal of Medical Case Reports 2011, 5:15
http://www.jmedicalcasereports.com/content/5/1/15
Page 5 of 5